NASDAQ: AKTSAktis Oncology Inc Stock
$27.88-0.54 (-1.9%)
Updated Jul 10, 2026
AKTS Price
$27.88
Fair Value Price
$0.50
Market Cap
$1.49B
52 Week Low
$14.72
52 Week High
$34.19
P/E
N/A
P/B
2.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
N/A
Beta
1.61
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AKTS Overview
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKTS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important AKTS news, forecast changes, insider trades & much more!
AKTS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKTS ($27.88) is overvalued by 5,481.34% relative to our estimate of its Fair Value price of $0.50 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AKTS ($27.88) is not significantly undervalued (5,481.34%) relative to our estimate of its Fair Value price of $0.50 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AKTS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more AKTS due diligence checks available for Premium users.
Valuation
AKTS fair value
Fair Value of AKTS stock based on Discounted Cash Flow (DCF)
Price
$27.88
Fair Value
$0.50
Overvalued by
5,481.34%
AKTS ($27.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKTS ($27.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AKTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.94x
Industry
5.52x
AKTS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKTS's financial health
Profit margin
Revenue
$3.2M
Net Income
-$18.3M
Profit Margin
-567.9%
Assets to liabilities
Assets
$576.8M
Liabilities
$70.7M
Debt to equity
0.14
AKTS's short-term assets ($543.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTS's short-term assets ($543.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.2M
Investing
$20.5M
Financing
$337.5M
AKTS vs Biotech Stocks
Aktis Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.